ArticleFrontiers in sports and active living2026
Reported use of anti-asthmatic medication in doping control forms from 2015 to 2019 - mapping retrospective data.
Article in Frontiers in sports and active living, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Asthma and bronchial hyperresponsiveness is common in athletes, particularly in sports with high ventilatory demands or exposure to irritants such as cold, dry air, polluted air, or trichloramines. The mechanisms behind asthma in athletes remain unclear, but repeated high-volume ventilation and exposures to irritants, as well as airway inflammation and remodelling likely contribute. Symptoms resemble those of asthma, and airway hyperresponsiveness plays a key role, even in athletes with no other classic asthma features. Treatment of asthma in athletes follows the same approach as asthma in the general population. Use of asthma medication is commonly reported by athletes on doping control forms (DCFs). Thus, this study aimed to investigate the use of different anti-asthmatic medications among doping-controlled athletes. Methods: This was an observational cross-sectional study, evaluating retrospective data from athletes' DCFs obtained during 2015-2019 as part of Anti-doping Norway's national testing program in Norwegian sport, some of whom reappearing in the data set with multiple forms. Results: Of 10 418 DCFs, 1702 (16.3%) contained one or more anti-asthmatic medications. Bronchodilators were most frequently reported, with anticholinergics being most common. DCFs reported from females, national level athletes, and athletes with high risk of asthma contained significantly more anti-asthmatic medications compared to their counterparts ( Conclusion: Despite the limitation of athletes' reappearance in the dataset, this study provides insight into guideline adherence and asthma medication use among athletes in Norway. Further research is needed in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.